Arcellx, Inc. (NASDAQ:ACLX – Get Free Report)’s share price rose 5.1% on Wednesday after UBS Group raised their price target on the stock from $106.00 to $114.00. UBS Group currently has a buy rating ...

I just returned from San Diego and the annual meeting of the American Society of Hematology, where Arcellx won the battle of ...

Highlights:,Arcellx, Inc.,(NASDAQ:ACLX),experienced a 5.1% increase in its stock price.,UBS Group raised its price target for ...

Arcellx (NASDAQ:ACLX – Get Free Report)‘s stock had its “buy” rating reiterated by HC Wainwright in a note issued to ...

SAN DIEGO – Gilead Sciences and Arcellx's autologous B-cell maturation antigen (BCMA)-directed CAR T-cell therapy ...

With nearly 90% of patients showing no detectable cancer cells after treatment, J&J and Legend’s Carvykti could stave off ...

In a report released today, Richard Newitter from Truist Financial maintained a Buy rating on Arcellx Inc (ACLX – Research Report). The ...

GSK, Gilead and Arcellx, Vertex and more present new data at the American Society of Hematology annual meeting just as sickle cell therapies Casgevy and Lyfgenia have a new outcomes-based payment ...

In a report released yesterday, Judah Frommer from Morgan Stanley maintained a Buy rating on Arcellx Inc (ACLX – Research Report), with a price ...

There are two cell therapies approved in this patient setting, Johnson & Johnson’s Carvykti and Bristol Myers Squibb's Abecma ...

The feud between Arcellx and Legend Biotech over their anti-BCMA CAR-T therapies for multiple myeloma is getting extra spicy ...

NewAmsterdam Pharma said Tuesday its cholesterol drug lowered the risk of major cardiovascular events and the biotech stock ...